The Effectiveness of a Thyme and Honey Spray for Oral Toxicities
- Conditions
- Cancer of the Head and NeckXerostomiaRadiation ToxicityOral Mucositis
- Interventions
- Dietary Supplement: Placebo oral sprayDietary Supplement: Thyme and Honey-based oral spray
- Registration Number
- NCT04880148
- Lead Sponsor
- Cyprus University of Technology
- Brief Summary
Aim: To evaluate the effectiveness of thymus honey on radiation induced-oral mucositis and xerostomia.
Background: Oral mucositis and xerostomia are two of the most severe side effects that head and neck cancer patients confront during and after the completion of radiotherapy. Although several medications are used for their treatment, these fail to provide a fully effective and comprehensive management. Honey and thyme have been studied for the management of various treatment-related side effects.
Design: Α double blinded randomised controlled trial will be used for this study.
Methods: 200 head and neck cancer patients who receive radiotherapy will be included in this study. Patients will be randomised and divided into two equal groups of 100 participants; the intervention group (oral spray with thyme and honey + standard care) and the control group ( placebo spray + standard care). Assessments with xerostomia and oral mucositis scales additionally to 4 self-administered questionnaires will occur in both groups at baseline and then weekly and 6 months following completion of treatment. The duration of the study will be 3 years from the day of approval of this research protocol.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Patients with a confirmed histologic diagnosis of head and neck cancer
- Patients referred to non-palliative radiotherapy to the oral cavity will be included in the study
- Synchronous or induction chemotherapy, or both, will be permitted.
- Patients aged over 18,
- Patients able to provide informed consent,
- Patients having radiotherapy for at least three weeks (lower limit has been set at 50 Gy),
- Patients able to complete records accurately
- Patients with a confirmed and medically treated diabetes mellitus,
- Patients with allergy to honey, thyme or any other ingredient,
- Patients who will refuse to take part in this study and
- Patients with previous radiotherapy or presence of systemic disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo oral spray Placebo oral spray Placebo oral spray Thyme and Honey-based oral spray Thyme and Honey-based oral spray Thyme and Honey-based oral spray
- Primary Outcome Measures
Name Time Method Change from baseline in Mucositis Grade (RTOG) at weekly assessments Baseline (week 4), week 5, week 6, week 7, week 8 and week 24 The scale includes 5 grades (from 0 to IV). Higher grade denotes more severe mucositis
Change from baseline in Xerostomia Grade (CTCAE) at weekly assessments Baseline (week 4), week 5, week 6, week 7, week 8 and week 24 he scale includes 5 grades (from 0 to IV). Higher grade denotes more severe xerostomia
- Secondary Outcome Measures
Name Time Method Change from baseline in Xerostomia Questionnaire (Dirix et al) Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy consists of three parts. In the first part, patients rate on a 4-likert scale (0, 1, 2, 3) the intensity of xerostomia, oral pain, taste, and dysphagia they experience and whether they suffered from more intense tooth decay or other related problems. Secondly, patients evaluate the impact of xerostomia on their Quality of Life. The Quality of Life (QoL) scales contains 15 items (ranging from 1 to 5) with a higher score indicating a worst QoL level (minimum score is 15 and the maximum is 75). Finally, patients rate the degree to which they suffered from xerostomia on a 100-mm Visual Analogue Scale (VAS).
Change from baseline in Oral Mucositis Questionnaire (OMWQ) Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy The 12-item questionnaire is designed to evaluate the overall wellbeing of the patient relating to OM during the last week. Possible answers are scored on Likert scales containing 5, 7 and 11 points. The first 2 questions assess global health and quality of life (QOL). The questions are rated on a 7-point scale, with 1 indicating very poor and 7 indicating excellent. The fourth question, which is made up of 6 items, addresses the impact of MTS on patient function and includes a 5-point scale, with 0 indicating not limited and 4 indicating unable to do. The remaining 3 questions assess the degree of mouth and throat pain and soreness using an 11-point scale, with 0 indicating no pain or soreness and 10 indicating the worst pain or soreness imaginable or possible.
Change from baseline in health-related QoL (EORTC QLQ-C30) questionnaire Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy The EORTC QLQ-C30 is a cancer-specific self-report questionnaire and comprises a global QOL scale (two items), five functional scales, three symptom scales and six single items. Scores QLQ-C30 are linearly transformed to a scale of 0-100, with a higher score indicating a better level of functioning or global QOL, or a worse level of symptoms or problems
Change from baseline in health-related QoL (EORTC QLQ-H&N43) questionnaire Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy The EORTC QLQ-H\&N35 module covers specific head and neck issues, comprises ten single items and seven subscales: swallowing, senses, speech, social eating, social contact and sexuality. QLQ-H\&N35 are linearly transformed to a scale of 0-100, with a higher score indicating a better level of functioning or global QOL, or a worse level of symptoms or problem.
Trial Locations
- Locations (2)
German Oncology Center
🇨🇾Limassol, Cyprus
Bank of Cyprus Oncology Center
🇨🇾Nicosia, Cyprus